CTOs on the Move

Codiak Biosciences

www.codiakbio.com

 
Codiak is the leader in the emerging field of exosome therapeutics, working to harness the power of this cellular messenger system to create potentially life-changing medicines. A venture-backed startup founded in 2015, Codiak has rapidly built a proprietary technology platform for exosome engineering and manufacturing that allows for precise targeting of important molecular pathways, opening the door to the development of therapies for cancer and other diseases. Led by an experienced and dedicated team, Codiak has at its foundation a positive and collaborative culture that is deeply rooted in cutting edge science and promotes opportunity for growth. Recent discoveries have ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.codiakbio.com
  • 500 Technology Square 9th Floor
    Woburn, MA USA 02139
  • Phone: 617.949.4100

Executives

Name Title Contact Details
Konstantin Konstantinov
Chief Technology Officer Profile

Funding

Codiak Biosciences raised $31M on 11/25/2015
Codiak Biosciences raised $76.5M on 11/29/2017
Codiak Biosciences raised $66.4M on 02/11/2021

Similar Companies

ProtonDx

Because your organisation needs certainty when testing for Covid-19

Revel

Apps that work seamlessly together to create integrated, multichannel programs that empower people to take a dramatically more active role in improving health. Beyond members and patients, this is healthcare IT that helps doctors, providers, health plan administrators and medical device manufacturers. Not to mention Medicare Star Ratings.

twoXAR

twoXAR is an artificial intelligence-driven drug discovery company.

Akaza Research

Akaza Research is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cornerstone BioPharma

At Cornerstone BioPharma, we are constantly striving to make good medicines better. We know that Healthcare providers and patients are concerned about the safety of today's medications-that makes tried and true medications very appealing. However, due to